Cadegiani: An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial

Cadegiani, 270 patient spironolactone antiandrogen early treatment study: 77% faster recovery [p=0.006] and 38% faster viral clearance [p=0.02] https://c19p.org/cadegiani9

copied to clipboard

An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial

Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870 (Preprint)

6 Oct 2020 Source PDF Share Tweet

Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spironolactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared to both other HA patients and non-HA patients. SOC included other treatments and there was no mortality or hospitalization.

Important missing comments or errors? Let us know.

recovery time, 76.7% lower, relative time 0.23, p = 0.006, treatment 8, control 262, excluding anosmia.

recovery time, 82.8% lower, relative time 0.17, p = 0.002, treatment 8, control 262, including anosmia.

time to viral-, 37.9% lower, relative time 0.62, p = 0.02, treatment 8, control 262.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

This study is excluded in the after exclusion results of meta analysis: significant unadjusted differences between groups.

Cadegiani et al., 6 Oct 2020, prospective, Brazil, preprint, 4 authors, average treatment delay 3.0 days.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Antiandrogens All

Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit